INS and Hypoglycemia: iGlarLixi has also demonstrated improved glycaemic control, weight benefit and reduced risk of hypoglycaemia versus the premixed insulin, biphasic insulin aspart 30/70 (BIAsp 30), in people with T2D suboptimally controlled on basal insulin plus OADs.9